Evidence map›Paper›PMID 37930310›Full record

ArticlemAbs

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C

John D Bagert, Vaheh Oganesyan, Chi-I Chiang, Mike Iannotti, Jia Lin, Chunning Yang, Sterling Payne, Will McMahon, Samuel Edwards, Andrew Dippel and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

John D BagertBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Vaheh OganesyanBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Chi-I ChiangBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Mike IannottiBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Jia LinBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Chunning YangBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Sterling PayneBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Will McMahonProcess and Analytical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Samuel EdwardsProcess and Analytical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Andrew DippelBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Mark HutchinsonBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Fengying HuangBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Vineela AletiBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Chendi NiuBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Chen QianBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Jessica DenhamBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Sofia FerreiraResearch and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Pallab PradhanBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Mark PenneyResearch and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Chunlei WangBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Wenhai LiuBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Even WalsengBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
Yariv MazorBiologics Engineering, AstraZeneca, Gaithersburg, MD, USA.

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provide favorable pharmacology and pharmacokinetic profiles. The production of correctly assembled asymmetric monovalent bsIgGs, however, is a complex engineering endeavor due to the propensity for non-cognate heavy and light chains to mis-pair. Previously, we introduced the DuetMab platform as a general solution for the production of bsIgGs, which utilizes an engineered interchain disulfide bond in one of the C

Indexed as

Antibodies, BispecificDisulfidesImmunoglobulin GMutationStatic ElectricityAntibodies, BispecificDisulfidesImmunoglobulin GAntibodybispecificchainchargeDuetMabelectrostaticengineeringlambdapairingsteering

Identifiers

PMID37930310
PMCPMC10629431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.